Imagine a future where a simple shot could ease your pet’s chronic pain, just like advanced treatments do for humans. That future might be closer than we think for our furry friends. Gallant, a San Diego-based startup, recently made waves by announcing an $18 million funding round. This money is earmarked to push their pet stem cell therapies through the crucial first stage of FDA review. If they get the green light, it could open up entirely new ways to treat common pet ailments.
Stem cell research for human medicine has been ongoing for decades. Gallant, founded over seven years ago, is bringing that same innovative spirit to veterinary care. Their initial focus is on Feline Chronic Gingivostomatitis (FCGS), a painful inflammation of a cat’s mouth. They expect to receive approval for this treatment by early 2026.
The company has also seen promising results in dogs suffering from arthritis, a condition that causes severe pain and makes movement difficult. Their research showed reduced pain and improved mobility in these canine patients, with effects lasting up to two years. However, when they tried similar methods for kidney disease in cats, the outcomes were less certain. Research is rarely a straight line.
What makes Gallant’s approach stand out is their use of “allogeneic” stem cells. This means they use stem cells from a single donor’s uterus, specifically from an animal of the same species. From just one donor, they can create a massive supply—up to 30 million doses. This method makes it much easier to scale production compared to other techniques used before.
This incredible scalability certainly caught the eye of investors. The latest funding round brought back Digitalis Ventures, a previous investor, and welcomed NovaQuest Capital Management. NovaQuest’s involvement is significant, as they have a strong background in investing in human stem cell therapies. This shows how seriously the financial world is taking the potential of this technology for pets.
Gallant’s journey has its own unique story. The company was founded by Aaron Hirschhorn, who previously sold his pet-sitting company, DogVacay, to competitor Rover. Sadly, Aaron passed away in 2021. Linda Black, who was with Gallant from its early days, stepped up to become President and Chief Scientist, leading the company today. Since its start, Gallant has now raised at least $44 million in total funding.